Skip to main content

Table 1 Pharmacokinetic analysis of ACY-1083

From: Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment

 

ACY-1083 plasma concentration

ACY-1083 Brain concentration

Brain to plasma ration

Dose (mg/kg)

Dose route

Sampling

time (hr)

Mean (ng/mL)

SD

CV (%)

Mean (ng/g)

SD

CV (%)

Mean

SD

CV (%)

5

IP

Predose

NA

NA

NA

NA

NA

NA

BQL

NA

NA

  

0.08

654.33

58.71

8.97

44.13

11.68

26.46

0.07

0.01

18.72

  

0.25

936.00

91.43

9.77

109.50

10.26

9.37

0.12

0.01

4.27

  

1

180.00

11.00

6.11

112.33

8.08

7.20

0.63

0.08

13.33

  

4

78.30

7.39

9.44

15.17

2.41

15.88

0.20

0.04

22.38

  1. Abbreviations: BQL below the quantifiable limit of 1.00 ng/mL of ACY-1083 in mouse plasma and brain homogenates, CV coefficient of variation, NA not available, SD standard deviation